Received Mar 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| SMALLMNK | SMALLPOX + MONKEYPOX (JYNNEOS) | BAVARIAN NORDIC | 1 | Unknown | IM |
The patient recieved first dose of Jynneos vaccine intramuscularly; Case reference number US-BN-2024-002741 is a spontaneous case initially received from other health care professional via Communications (reference number: USBAV24-2932) on 06-Nov-2024 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 06-Nov-2024, the patient was vaccinated with a first dose of Jynneos (batch number: unknown and expiration date: unknown), at an unknown dose, intramuscularly at unknown site of administration, for an unknown indication (explicitly coded as 'inappropriate route of vaccination'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Jynneos vaccine. Non-significant case correction downloaded from VAERS on 09-Dec-2024 included additional reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241106-39577c to US-BAVARIAN NORDIC A/S-US-BN-2024-002741, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A male patient of unspecified age was vaccinated with the first dose of Jynneos, intramuscularly, for an unknown indication, which is considered as inappropriate route of vaccination. It was unknown if the patient experienced any adverse event due to Jynneos vaccine. Incorrect route of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Incorrect route of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age was vaccinated with the first dose of Jynneos, intramuscularly, for an unknown indication, which is considered as inappropriate route of vaccination. It was unknown if the patient experienced any adverse event due to Jynneos vaccine. Incorrect route of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Incorrect route of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.